RxSight (RXST) Enterprise Value (2020 - 2025)
RxSight (RXST) has disclosed Enterprise Value for 6 consecutive years, with -$228.1 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value rose 50.16% year-over-year to -$228.1 million, compared with a TTM value of -$228.1 million through Dec 2025, up 50.16%, and an annual FY2025 reading of -$228.1 million, up 50.16% over the prior year.
- Enterprise Value was -$228.1 million for Q4 2025 at RxSight, down from -$197.9 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$81.7 million in Q2 2021 and bottomed at -$457.7 million in Q4 2024.
- Average Enterprise Value over 5 years is -$232.8 million, with a median of -$228.1 million recorded in 2025.
- The sharpest move saw Enterprise Value soared 68.17% in 2024, then tumbled 364.51% in 2025.
- Year by year, Enterprise Value stood at -$159.3 million in 2021, then decreased by 25.38% to -$199.8 million in 2022, then decreased by 19.87% to -$239.5 million in 2023, then tumbled by 91.15% to -$457.7 million in 2024, then surged by 50.16% to -$228.1 million in 2025.
- Business Quant data shows Enterprise Value for RXST at -$228.1 million in Q4 2025, -$197.9 million in Q3 2025, and -$227.5 million in Q2 2025.